Literature DB >> 18376380

Molecular analysis-based treatment strategies for non-small cell lung cancer.

Gerold Bepler1, Mubeena Begum, George R Simon.   

Abstract

BACKGROUND: Lung cancer is the leading cause of cancer-related mortality. Improved understanding in the molecular biology and genetics of lung cancer has resulted in the identification of individual genes, gene expression profiles, and molecular pathways that may be useful for clinical management decisions.
METHODS: We focused on recent molecules and platforms under evaluation for implementation into clinical decision making.
RESULTS: Prognostic molecular parameters are defined as markers that impact overall outcome in terms of survival independent of therapeutic interventions. Predictive molecular parameters are defined as markers that impact therapeutic efficacy.
CONCLUSIONS: Several molecules and profiles are emerging with promising utility as predictive and prognostic parameters in non-small cell lung cancer independent of the standard clinical parameters, such as stage, performance status, and gender. These include the genes ERCC1, RRM1, and BRCA1, which are involved in nucleotide metabolism and DNA damage repair, epidermal growth factor receptor, which is involved in cell proliferation and survival, and oligonucleotide expression array profiles, which are signatures of global gene expression associated with specific tumor phenotypes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18376380     DOI: 10.1177/107327480801500205

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  9 in total

1.  Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration.

Authors:  Rex Chin Wei Yung; Susan Otell; Peter Illei; Douglas P Clark; David Feller-Kopman; Lonny Yarmus; Frederic Askin; Edward Gabrielson; Qing Kay Li
Journal:  Cancer Cytopathol       Date:  2011-12-05       Impact factor: 5.284

2.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

3.  Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors.

Authors:  Yanping Wu; Lianjun Lin; Xinmin Liu
Journal:  Dis Markers       Date:  2020-06-09       Impact factor: 3.434

Review 4.  Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer.

Authors:  Catherine Gérard; Channa Debruyne
Journal:  Mol Oncol       Date:  2009-09-10       Impact factor: 6.603

Review 5.  Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: current status and future directions.

Authors:  George R Simon
Journal:  Curr Treat Options Oncol       Date:  2009-03-06

6.  A patient-derived xenograft mouse model generated from primary cultured cells recapitulates patient tumors phenotypically and genetically.

Authors:  Hyang Sook Seol; Young-Ah Suh; Young-Joon Ryu; Hyun Jung Kim; Sung Min Chun; Deuk Chae Na; Hiroshi Fukamachi; Seong-Yun Jeong; Eun Kyung Choi; Se Jin Jang
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-02       Impact factor: 4.553

7.  Progress in personalizing chemotherapy for bladder cancer.

Authors:  James S Chang; Primo N Lara; Chong-Xian Pan
Journal:  Adv Urol       Date:  2012-02-13

Review 8.  Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.

Authors:  Aniello Cerrato; Francesco Morra; Angela Celetti
Journal:  J Exp Clin Cancer Res       Date:  2016-11-24

9.  Near-Infrared Light-Triggered Thermosensitive Liposomes Modified with Membrane Peptides for the Local Chemo/Photothermal Therapy of Melanoma.

Authors:  Xinxin Li; Chunsheng Yang; Yingkai Tao; Xiaoyang Hou; Yanqun Liu; Hong Sang; Guan Jiang
Journal:  Onco Targets Ther       Date:  2021-02-25       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.